Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

CARMEL, Ind., Oct. 09, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
October 03, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting

CARMEL, Ind., Oct. 03, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
September 11, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults

MBX 2109 was observed to be generally well-tolerated MBX 2109 increased albumin adjusted serum calcium and suppressed endogenous PTH(1-84) CARMEL, Ind., Sept. 11, 2023 (GLOBE NEWSWIRE) -- MBX...
August 29, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in Morgan Stanley Global Healthcare Conference

CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
August 07, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

CARMEL, Ind., Aug. 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
July 10, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer

CARMEL, Ind., July 10, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
May 24, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in Jefferies Healthcare Conference

CARMEL, Ind., May 24, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
May 08, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in May Investor Conferences

CARMEL, Ind., May 08, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
April 10, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference

CARMEL, Ind., April 10, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
March 07, 2023 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

CARMEL, Ind., March 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right